               SEQUENCE LISTING



<110> R.G.C.C. Holdings AG



<120> Novel CoV-2 Antibodies



<130> F06326/JS



<160> 4



<170> BiSSAP 1.3.6



<210> 1

<211> 15

<212> PRT

<213> SARS-CoV-2





<220> 

<223> Designed peptide based on spike protein AA sequence 326-340



<400> 1

Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu 

1               5                   10                  15  



<210> 2

<211> 15

<212> PRT

<213> SARS-CoV-2





<220> 

<223> Designed peptide based on spike protein AA sequence 449-463



<400> 2

Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro 

1               5                   10                  15  



<210> 3

<211> 9

<212> PRT

<213> SARS-CoV-2





<220> 

<223> Designed peptide based on spike protein AA sequence 718-726



<400> 3

Phe Thr Ile Ser Val Thr Thr Glu Ile 

1               5                   



<210> 4

<211> 9

<212> PRT

<213> SARS-CoV-2





<220> 

<223> Designed peptide based on envelope protein AA sequence 2-10



<400> 4

Tyr Ser Phe Val Ser Glu Glu Thr Gly 

1               5                   



